Seminars in Cancer Biology

Article	Citations
Editorial Board	445
Advances in biology and novel treatments of SCLC	431
Small secretory proteins of immune cells can modulate gynecological cancers	327
Unveiling the role of PIK3R1 in cancer: A comprehensive review of regulatory signaling and therapeutic implications	255
Critical DNA damaging pathways in tumorigenesis	237
Emerging applications of bacteria as antitumor agents	230
Deregulated transcription factors in the emerging cancer hallmarks	218
Updated review on green tea polyphenol epigallocatechin-3-gallate as a cancer epigenetic regulator	217
Carbonic anhydrase IX: A tumor acidification switch in heterogeneity and chemokine regulation	215
The molecular chaperone TRAP1 in cancer: From the basics of biology to pharmacological targeting	209
Biology of cancer; from cellular and molecular mechanisms to developmental processes and adaptation	199
Targeting Hippo signaling pathway by phytochemicals in cancer therapy	188
Multifaceted role of chemokines in solid tumors: From biology to therapy	185
Editorial Board	182
Editorial Board	180
PIWI-interacting RNAs in human cancer	179
Origins and molecular effects of hypoxia in cancer	177
Molecular targets of tyrosine kinase inhibitors in thyroid cancer	171
Excess body weight and postmenopausal breast cancer: Emerging molecular mechanisms and perspectives	170
The IL-1 family in tumorigenesis and antitumor immunity	169
Erratum to “RNA regulatory mechanisms controlling TGF-β signaling and EMT in cancer” [Semin. Cancer Biol. 102–103 (2024) 4–16]	167
Special issue: Deregulated transcription factors in the cancer therapeutic challenges: An update on cancer stemness features	157
Targeting micro-environmental pathways by PROTACs as a therapeutic strategy	150
Innovative trial design in precision oncology	149
Immune cellular components and signaling pathways in the tumor microenvironment	141

Multifaceted functions of chronic inflammation in regulating tumor dormancy and relapse	140
Thinking small to win big? A critical review on the potential application of extracellular vesicles for biomarker discovery and new therapeutic approaches in pancreatic cancer	137
Microbiome dysbiosis and epigenetic modulations in lung cancer: From pathogenesis to therapy	137
Association of Chlamydia and Mycoplasma infections with susceptibility to ovarian cancer: A systematic review and meta-analysis	137
Enhancing head and neck tumor management with artificial intelligence: Integration and perspectives	134
Extracellular vesicles associated microRNAs: Their biology and clinical significance as biomarkers in gastrointestinal cancers	134
Targeting monocarboxylate transporters (MCTs) in cancer: How close are we to the clinics?	127
Gut microbes in gastrointestinal cancers	124
Genome chaos: Creating new genomic information essential for cancer macroevolution	122
Anticancer properties of chimeric HDAC and kinase inhibitors	117
New biological and immunological approaches to cancer therapy: Basic and clinical aspects	116
Reprogramming of glycolysis by chemical carcinogens during tumor development	114
Multi-omic markers of intraductal papillary mucinous neoplasms progression into pancreatic cancer	113
Editorial Board	111
Therapy-induced modulation of extracellular vesicles in hepatocellular carcinoma	111
Anticancer natural products targeting immune checkpoint protein network	111
Vibrational spectroscopy for decoding cancer microbiota interactions: Current evidence and future perspective	111
Metabolic landscape and rewiring in normal hematopoiesis, leukemia and aging	110
Insight into the role of multiple signaling pathways in regulating cancer stem cells of gynecologic cancers	109
The role of deiodinases on metabolic alteration in cancer	108
The intricacies of NRF2 regulation in cancer	106
Targeting the “undruggable”: RNA-binding proteins in the spotlight in cancer therapy	105
Unravelling the complexities of resistance mechanism in pancreatic cancer: Insights from in vitro and ex-vivo model systems	105
Cancer cell heterogeneity & plasticity in glioblastoma and brain tumors	104
Extracellular vesicles in glioblastoma: Biomarkers and therapeutic tools	104
How far have we explored fungi to fight cancer?	103
Modulation of the tumor microenvironment by natural agents: implications for cancer prevention and therapy	103
Cellular stress responses and metabolic reprogramming in cancer progression and dormancy	102
Regulation of epithelial-mesenchymal transition by tumor microenvironmental signals and its implication in cancer therapeutics	101
Advancement of cancer immunotherapy using nanoparticles-based nanomedicine	100
Curcumin and colorectal cancer: An update and current perspective on this natural medicine	99
Atrial fibrillation in cancer patients: Epidemiology, identification and management	97
Role of LDH in tumor glycolysis: Regulation of LDHA by small molecules for cancer therapeutics	95
Attacking the PI3K/Akt/mTOR signaling pathway for targeted therapeutic treatment in human cancer	94
Editorial Board	94
Regulation of the aryl hydrocarbon receptor in cancer and cancer stem cells of gynecological malignancies: An update on signaling pathways	94
Editorial Board	93
Cytotoxic activity of l-lysine alpha-oxidase against leukemia cells	93
Transcription networks rewire gene repertoire to coordinate cellular reprograming in prostate cancer	92
The role of RNA processing and regulation in metastatic dormancy	92
BubR1 and SIRT2: Insights into aneuploidy, aging, and cancer	89
Mechanisms and applications of apolipoproteins and apolipoprotein mimetic peptides: Common pathways in cardiovascular disease and cancer	89
Plant lectins and their usage in preparing targeted nanovaccines for cancer immunotherapy	88
The foundational framework of tumors: Gametogenesis, p53, and cancer	87
The role of tumor microenvironment and exosomes in dormancy and relapse	86
Chaperonins in cancer: Expression, function, and migration in extracellular vesicles	85
Benefits and limitations of nanomedicine treatment of brain cancers and age-dependent neurodegenerative disorders	84
Role of ubiquitination-driven metabolisms in oncogenesis and cancer therapy	84
The microbiome-immune cell interaction network: Advancing tumor immunotherapy	81
Emerging roles of long noncoding RNAs in chemoresistance of pancreatic cancer	79

Leveraging epigenetic alterations in pancreatic ductal adenocarcinoma for clinical applications	79
Artificial intelligence and pathology: From principles to practice and future applications in histomorphology and molecular profiling	79
Clinical utility of whole-genome sequencing in precision oncology	78
Epithelial-mesenchymal transition: Insights into nickel-induced lung diseases	78
Analytical demands to use whole-genome sequencing in precision oncology	78
Drivers of centrosome abnormalities: Senescence progression and tumor immune escape	78
Emerging perspectives on growth factor metabolic relationships in the ovarian cancer ascites environment	78
Advancements in small cell lung cancer	77
Functionalized-DNA nanostructures as potential targeted drug delivery systems for cancer therapy	76
Microbiota and lung cancer	76
Metabolic reprogramming of tumor microenviroment by engineered bacteria	75
Novel molecular regulators of breast cancer stem cell plasticity and heterogeneity	74
Pattern recognition of tumor dormancy and relapse beyond cell-intrinsic and cell-extrinsic pathways	74
Holistic immunomodulation for small cell lung cancer	73
Chemopreventive effects of anthocyanins on colorectal and breast cancer: A review	72
Arsenic co-carcinogenesis: Inhibition of DNA repair and interaction with zinc finger proteins	71
Sanitation enzymes: Exquisite surveillance of the noncanonical nucleotide pool to safeguard the genetic blueprint	70
Anticancer activity of lactic acid bacteria	70
Paradoxes of cancer: Survival at the brink	70
Targeting OXPHOS and the electron transport chain in cancer; Molecular and therapeutic implications	69
Oncolytic viruses as a promising therapeutic strategy against the detrimental health impacts of air pollution: The case of glioblastoma multiforme	69
Cytokines chattering in pancreatic ductal adenocarcinoma tumor microenvironment	69
Targeting tumor cell senescence and polyploidy as potential therapeutic strategies	68
CRISPR/Cas mediated epigenome editing for cancer therapy	68
Molecular mechanisms of pulmonary carcinogenesis by polycyclic aromatic hydrocarbons (PAHs): Implications for human lung cancer	68
Urinary microbiota and bladder cancer: A systematic review and a focus on uropathogens	67
Excess body weight: Novel insights into its roles in obesity comorbidities	67
Microbes in gynecologic cancers: Causes or consequences and therapeutic potential	67
Targeting p53 for the treatment of cancer	67
Biomarkers, omics and artificial intelligence for early detection of pancreatic cancer	66
Special Issue: Epigenetic regulation of cancer progression: Promises and progress	66
Editorial Board	65
Editorial Board	65
Characterizing and exploiting the many roles of aberrant H2B monoubiquitination in cancer pathogenesis	64
Human cell polyploidization: The good and the evil	64
Targeting inflamed and non-inflamed melanomas: biological background and clinical challenges	64
Editorial Board	64
Non-coding genome in small cell lung cancer between theoretical view and clinical applications	63
SR-BI as a target of natural products and its significance in cancer	63
Beyond cell cycle regulation: The pleiotropic function of CDK4 in cancer	62
The crucial role of epigenetic regulation in breast cancer anti-estrogen resistance: Current findings and future perspectives	62
Deregulated transcription factors and poor clinical outcomes in cancer patients	61
Transfer RNA-derived small RNA: A rising star in oncology	61
The intricate role of adipokines in cancer-related signaling and the tumor microenvironment: Insights for future research	61
Exosome-based nanomedicine for cancer treatment by targeting inflammatory pathways: Current status and future perspectives	61
Thematic issue ‘tumor glycolysis’	60
The impact of VEGF on cancer metastasis and systemic disease	59
Accelerating antibody discovery and design with artificial intelligence: Recent advances and prospects	59
TGF-β, EMT, and resistance to anti-cancer treatment	59
Extracellular vesicles as source for the identification of minimally invasive molecular signatures in glioblastoma	58
Editorial Board	58
Mechanisms and strategies of immunosenescence effects on non-small cell lung cancer (NSCLC) treatment: A comprehensive analysis and future directions	58
Precision diagnostics in lymphomas – Recent developments and future directions	58
The role of RNA-binding proteins in the processing of mRNAs produced by carcinogenic papillomaviruses	58
Cathepsins: Emerging targets in the tumor ecosystem to overcome cancers	58
Putting the brakes on tumorigenesis with snake venom toxins: New molecular insights for cancer drug discovery	58
Contributions of the distinct biophysical phenotype of polyploidal giant cancer cells to cancer progression	57
Insights into the role of gut and intratumor microbiota in pancreatic ductal adenocarcinoma as new key players in preventive, diagnostic and therapeutic perspective	56
Transcriptional factors targeting in cancer stem cells for tumor modulation	55
Emerging role of pancreatic stellate cell-derived extracellular vesicles in pancreatic cancer	55
Remodeling of tumor microenvironment by cellular senescence and immunosenescence in cervical cancer	55
Microbes in lung cancer initiation, treatment, and outcome: Boon or bane?	55
The Warburg effect: The hacked mitochondrial-nuclear communication in cancer	55
Exosomes and extracellular vesicles: Rethinking the essential values in cancer biology	54
Epigenetic modifications of c-MYC: Role in cancer cell reprogramming, progression and chemoresistance	54
The intricate nature of senescence in development and cell plasticity	54
Role of endolysosome function in iron metabolism and brain carcinogenesis	54
cGAS/STING signalling pathway in senescence and oncogenesis	54
Inflammation-targeted nanomedicine against brain cancer: From design strategies to future developments	53
Alternative splicing in EMT and TGF-β signaling during cancer progression	53
Gut microbiota and immunosenescence in cancer	53
Obesity and main urologic cancers: Current systematic evidence, novel biological mechanisms, perspectives and challenges	53
Editorial Board	52
Editorial Board	52
Anti-inflammatory and anti-cancer activities of frankincense: Targets, treatments and toxicities	52
Artificial intelligence aids in development of nanomedicines for cancer management	52
Corrigendum to “How far have we explored fungi to fight cancer?” [86/Part 2 (2022) 976–989]	51
Multiple endocrine neoplasia type 1 (MEN-1) and neuroendocrine neoplasms (NENs)	51
Precision medicine in pediatric solid cancers	51
Editorial Board	51

Pro-tumoral functions of tumor-associated macrophage EV-miRNA	50
Minimal residual disease in advanced or metastatic solid cancers: The G0-G1 state and immunotherapy are key to unwinding cancer complexity	50
Nanoparticles: Attractive tools to treat colorectal cancer	49
The role of surgery in platinum-resistant ovarian cancer: A call to the scientific community	49
Regulation of cancer cell signaling pathways as key events for therapeutic relevance of edible and medicinal mushrooms	49
Small cell lung cancer: Novel treatments beyond immunotherapy	49
Dysregulated FOXM1 signaling in the regulation of cancer stem cells	48
Vitamin D: What role in obesity-related cancer?	48
“Time” for obesity-related cancer: The role of the circadian rhythm in cancer pathogenesis and treatment	48
The altered lipidome of hepatocellular carcinoma	48
A role for partial epithelial-to-mesenchymal transition in enabling stemness in homeostasis and cancer	48
Pancreatic neuroendocrine neoplasms (pNENs): Genetic and environmental biomarkers for risk of occurrence and prognosis	48
The role of exercise in obesity-related cancers: Current evidence and biological mechanisms	47
Inflammation targeted nanomedicines: Patents and applications in cancer therapy	47
New insights into KLFs and SOXs in cancer pathogenesis, stemness, and therapy	47
Epigenetic deregulation in cancer: Enzyme players and non-coding RNAs	46
Predictive biomarkers for response to immune checkpoint inhibition	46
Exploiting transcription factors to target EMT and cancer stem cells for tumor modulation and therapy	46
Hedgehog signaling mechanism and role in cancer	46
Targeting oncogenic transcription factors in skin malignancies: An update on cancer stemness and therapeutic outcomes	46
Nanoparticle-based drug delivery systems in cancer: A focus on inflammatory pathways	46
Natural products targeting the PI3K-Akt-mTOR signaling pathway in cancer: A novel therapeutic strategy	46
Ethical challenges of precision cancer medicine	45
Understanding RNA-binding proteins	45
Interplay of ferroptosis, cuproptosis, and PANoptosis in cancer treatment-induced cardiotoxicity: Mechanisms and therapeutic implications	45
Polyploid giant cancer cell characterization: New frontiers in predicting response to chemotherapy in breast cancer	45
Lipids and lipoproteins in the interstitial tissue fluid regulate the formation of dysfunctional tissue-resident macrophages: Implications for atherogenic, tumorigenic, and obesogenic processes	45
Recent advances of nanodrug delivery system in the treatment of hematologic malignancies	45